ASH 2021 | Evaluating response criteria in myelodysplastic syndromes
In this video, Andrew M. Brunner, MD, Massachusetts General Hospital, Boston, MA, shares some insights into the challenge of analyzing patient response in myelodysplastic syndromes (MDS) and the current response criteria used in this disease area. Dr Brunner mentions that although achieving complete remission (CR) results in a survival benefit, very few patients treated with hypomethylating agents (HMAs) actually end up achieving CR. Dr Brunner then draws focus on how researchers can identify other meaningful responses, as well as challenges in this field. Following this, Dr Brunner explains some results from an analysis that investigated the use of complete remission with hematological improvement (CRh) and marrow complete remission (mCR) as response criteria in a subset of patients. To conclude, Dr Brunner mentions the need to perform further large-scale analyses on CRh and blood count endpoints in order to help design future clinical trials in MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Aprea: Research Funding; AstraZeneca: Research Funding; Janssen: Research Funding; GSK: Research Funding; Keros Therapeutics: Consultancy; Agios: Consultancy; Acceleron: Consultancy; Takeda: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding.
